BioVie Inc.
General ticker "BIVI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.3M (TTM average)
BioVie Inc. follows the US Stock Market performance with the rate: 28.9%.
Estimated limits based on current volatility of 13.5%: low 1.17$, high 1.53$
Factors to consider:
- Total employees count: 13 (-7.1%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Product development failure, Regulatory and compliance, Capital shortage, Labor/talent shortage/retention
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-06-30 to 2028-06-29
- 2026-06-30 to 2027-06-30 estimated range: [1.40$, 3.15$]
- 2027-06-30 to 2028-06-29 estimated range: [0.95$, 2.26$]
Financial Metrics affecting the BIVI estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: -1.37 < Return on assets ratio (scaled to [-100,100]) of 0
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -0.07 < Investing cash flow per share per price, % of 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BIVI quotes
Long-term BIVI plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.18MM | $18.07MM | $22.65MM |
| Operating Income | $-32.18MM | $-18.07MM | $-22.65MM |
| Non-Operating Income | $-0.12MM | $0.52MM | $0.58MM |
| Interest Expense | $2.89MM | $0.33MM | $0.02MM |
| R&D Expense | $23.10MM | $9.27MM | $13.96MM |
| Income(Loss) | $-32.30MM | $-17.54MM | $-22.07MM |
| Net Income(Loss)* | $-32.12MM | $-17.54MM | $22,028.72MM |
| Stockholders Equity | $15.51MM | $19.01MM | $10,270,270.00MM |
| Assets | $25.21MM | $21.56MM | $14,250,462.00MM |
| Operating Cash Flow | $-27.95MM | $-19.03MM | $-19,024.81MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $14.53MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $17.80MM | $12.73MM | $10,457.63MM |
| Earnings Per Share** | $-71.09 | $-11.87 | $3,040.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.